AI Vivo

AI Vivo is a Cambridge, UK-based biotech research company that develops artificial intelligence systems and generates multi-modal omics data to build OrganoMaps — proprietary models that link organ-level disease biology with treatment interventions. The company's Organome technology ranks drug candidates based on their phenotypic effects at the tissue level, enabling pharmaceutical and biotech partners to identify and prioritize novel therapeutic candidates earlier in the discovery process. AI Vivo's AI-driven platform is designed to improve clinical success rates and shorten development timelines by grounding drug discovery decisions in human organ-level biology rather than in reductive single-target or cell-line assays. The company serves pharma companies and biotech firms seeking to accelerate the discovery of medicines for patients with unmet needs.